Thomas A. Lagace, Ph.D.
Affiliations: | 2004 | Dalhousie University, Halifax, Nova Scotia, Canada |
Area:
Molecular BiologyGoogle:
"Thomas Lagace"Mean distance: (not calculated yet)
Parents
Sign in to add mentorNeale Ridgway | grad student | 2004 | Dalhousie University | |
(Regulation of phosphatidylcholine synthesis by cellular metabolites and enzyme localization.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Rasheed A, Robichaud S, Nguyen MA, et al. (2020) Loss of MLKL (Mixed Lineage Kinase-Like Domain Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. ATVBAHA119313640 |
Sarkar SK, Foo ACY, Matyas A, et al. (2020) A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles. The Journal of Biological Chemistry |
Lagace TA. (2015) Phosphatidylcholine: Greasing the Cholesterol Transport Machinery. Lipid Insights. 8: 65-73 |
Alghamdi RH, O'Reilly P, Lu C, et al. (2015) LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation. European Journal of Medicinal Chemistry. 92: 890-907 |
Lagace TA. (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Current Opinion in Lipidology. 25: 387-93 |
Nguyen MA, Kosenko T, Lagace TA. (2014) Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. Journal of Lipid Research. 55: 266-75 |
Lagace TA, Ridgway ND. (2013) The role of phospholipids in the biological activity and structure of the endoplasmic reticulum. Biochimica Et Biophysica Acta. 1833: 2499-510 |
Kosenko T, Golder M, Leblond G, et al. (2013) Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. The Journal of Biological Chemistry. 288: 8279-88 |
Lakoski SG, Lagace TA, Cohen JC, et al. (2009) Genetic and metabolic determinants of plasma PCSK9 levels. The Journal of Clinical Endocrinology and Metabolism. 94: 2537-43 |
McNutt MC, Kwon HJ, Chen C, et al. (2009) Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. The Journal of Biological Chemistry. 284: 10561-70 |